Epstein-Barr virus reactivation is a potentially severe complication in chronic lymphocytic leukemia patients with poor prognostic biological markers and fludarabine refractory disease.
Rath
Julie
J
Geisler
Christian
C
Christiansen
Claus B
CB
Hastrup
Nina
N
Madsen
Hans O
HO
Andersen
Mette K
MK
Pedersen
Lone B
LB
Jurlander
Jesper
J
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D019008:Drug Resistance, Neoplasm; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000821:virology*; D005260:Female; D004854:Herpesvirus 4, Human / Q000502:physiology*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014775:Virus Activation
D014408:Biomarkers, Tumor; D014740:Vidarabine; C024352:fludarabine